BDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity ...

During the first quarter, the Harbor Health Care ETF returned 2.18% (NAV), outperforming the Russell 3000® Growth Health Care ...

- Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. - ...

Theravance Biopharma (NASDAQ:TBPH) and partner Mylan reached a settlement agreement with Eugia Pharma over a patent dispute ...

Innovent Biologics presents data from phase 1 PoC study of IBI363 to treat advanced NSCLC at 2025 ASCO: San Francisco Friday, June 6, 2025, 18:00 Hrs [IST] Innovent Biologics, Inc ...

Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly ...

Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the ...

ICH Q6B provides expectations and a clear framework for the structural characterization of biopharmaceutical products.

Cellectar’s IopofosineI 131 receives US FDA breakthrough therapy designation for treating Waldenstrom macroglobulinemia: Florham Park, New Jersey Friday, June 6, 2025, 17:00 Hrs ...

Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a ...

Katie Lakofsky, bioscience workforce director for UD and the Delaware Bioscience Association, is focused on building the ...

After a long winter, the start of summer is ushering in some much-needed sunshine, warmer weather and, for a handful of ...